Company intelligence / Profile preview
MicThera
- Ownership
- Private
- Development stage
- Preclinical
Overview
MicThera specializes in the discovery and development of microbial-derived therapeutics to improve prostate cancer treatments. Their research highlights the link between gut microbiota composition—specifically higher levels of Prevotella spp.—and better patient prognosis. The company aims to develop new therapies that prevent resistance in prostate cancer by harnessing bacterial effector molecules rather than traditional probiotics. They collaborate with the Institute of Oncology Research (IOR) in Bellinzona and have recently completed a €1 million seed round to advance their preclinical pipeline.
- Therapeutic areas
- Oncology
- Modalities
- Microbial-derived therapeuticsbacterial effector molecules (from Prevotella spp.)
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on MicThera.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MicThera.